Here's what I would really like Doc Lalezari to investigate in his new role -
Ebola as a candidate for treatment with Leronlimab.
Can you imagine the attention Leronlimab would get worldwide from kicking this disease's ass?
Question -
I don't believe that the Ebola virus exploited CCR5 directly like HIV but the development of the disease in the body reminded me of the Cytokine Storm that kills Covid-19 patients. Do macrophages run amok in Ebola infections?
ChatGPT -
Yes — very much so. Your analogy to the cytokine storm in severe COVID-19 is well grounded. Ebola is one of the clearer examples of a viral disease in which infected and dysregulated macrophages can contribute directly to the processes that make the illness life-threatening. Researchers have described this for decades, including in studies of infected nonhuman primates and human patients.
But there is a particularly interesting twist: Ebola doesn't simply make the immune system too active. It simultaneously drives damaging inflammation and disables important antiviral defenses.
## How macrophages contribute to severe Ebola
1. The virus infects macrophages and monocytes
These cells are among Ebola's early targets. Instead of efficiently containing the infection, infected cells can produce large amounts of inflammatory cytokines and chemokines. Those signals recruit additional immune cells, some of which can become additional targets for infection. 
2. Inflammatory signals amplify the damage
Among the mediators implicated are TNF-α, IL-1β, IL-6, CCL3, CCL4 and CCL5 (RANTES). These signals can recruit more immune cells, intensify inflammation and disrupt normal blood-vessel function.
3. The vascular system begins to fail
Inflammatory mediators can increase blood-vessel permeability, while macrophage-associated tissue-factor activity promotes abnormal coagulation. The resulting fluid loss, low blood pressure, clotting abnormalities and organ dysfunction can culminate in shock.
## The paradox: too much inflammation, too little effective immunity
Ebola can also impair dendritic cells, which normally help activate T cells and coordinate the adaptive immune response. Meanwhile, inflammatory mediators and other infection-related processes contribute to the death of uninfected bystander lymphocytes.
So a patient can have an enormous inflammatory response while still failing to mount an effective response to clear the virus. This is not merely an immune system working too hard; it is an immune system working in a profoundly dysregulated way.
## Why this brings us back to Leronlimab
Here is the connection I find most interesting.
CCL5, also known as RANTES, is one of the chemokines implicated in Ebola-associated inflammation, and it signals through CCR5 among other receptors. Leronlimab blocks CCR5.
That gives us a plausible hypothesis:
- Ebola infection stimulates the release of inflammatory chemokines.
- CCR5 signaling helps recruit certain immune cells into inflamed tissues.
- Blocking CCR5 might reduce some of the harmful recruitment and amplification of inflammation.
However, there is an important distinction: Leronlimab would not directly neutralize TNF-α, IL-6 or IL-1β, and blocking CCR5 would not eliminate all the pathways driving the cytokine storm. Some chemokines signal through other receptors, and some CCR5-dependent recruitment may be beneficial.
A further question is whether CCR5 blockade could interrupt a damaging feedback loop without impairing viral clearance. That is a testable hypothesis, not an established therapeutic effect.
### The experiment I would find most informative
I would want to know whether blocking CCR5 in an appropriate Ebola disease model reduces vascular leakage, coagulation abnormalities and organ injury, and whether that occurs without increasing viral load or delaying viral clearance. Survival would ultimately be a crucial outcome.
If the intervention improved those measures, it would provide a much stronger rationale for studying Leronlimab as an adjunct to antiviral treatment.
My conclusion: Your intuition is biologically sound. Ebola and severe COVID-19 share important features of immune dysregulation, and macrophages are central to Ebola pathogenesis.
CCR5 blockade is therefore a reasonable research hypothesis—but the critical question is whether CCR5-mediated inflammation is sufficiently important to alter the course of Ebola disease, rather than simply being one part of a much larger inflammatory network.
Ebola as a candidate for treatment with Leronlimab.
Can you imagine the attention Leronlimab would get worldwide from kicking this disease's ass?
Question -
I don't believe that the Ebola virus exploited CCR5 directly like HIV but the development of the disease in the body reminded me of the Cytokine Storm that kills Covid-19 patients. Do macrophages run amok in Ebola infections?
ChatGPT -
Yes — very much so. Your analogy to the cytokine storm in severe COVID-19 is well grounded. Ebola is one of the clearer examples of a viral disease in which infected and dysregulated macrophages can contribute directly to the processes that make the illness life-threatening. Researchers have described this for decades, including in studies of infected nonhuman primates and human patients.
But there is a particularly interesting twist: Ebola doesn't simply make the immune system too active. It simultaneously drives damaging inflammation and disables important antiviral defenses.
## How macrophages contribute to severe Ebola
1. The virus infects macrophages and monocytes
These cells are among Ebola's early targets. Instead of efficiently containing the infection, infected cells can produce large amounts of inflammatory cytokines and chemokines. Those signals recruit additional immune cells, some of which can become additional targets for infection. 
2. Inflammatory signals amplify the damage
Among the mediators implicated are TNF-α, IL-1β, IL-6, CCL3, CCL4 and CCL5 (RANTES). These signals can recruit more immune cells, intensify inflammation and disrupt normal blood-vessel function.
3. The vascular system begins to fail
Inflammatory mediators can increase blood-vessel permeability, while macrophage-associated tissue-factor activity promotes abnormal coagulation. The resulting fluid loss, low blood pressure, clotting abnormalities and organ dysfunction can culminate in shock.
## The paradox: too much inflammation, too little effective immunity
Ebola can also impair dendritic cells, which normally help activate T cells and coordinate the adaptive immune response. Meanwhile, inflammatory mediators and other infection-related processes contribute to the death of uninfected bystander lymphocytes.
So a patient can have an enormous inflammatory response while still failing to mount an effective response to clear the virus. This is not merely an immune system working too hard; it is an immune system working in a profoundly dysregulated way.
## Why this brings us back to Leronlimab
Here is the connection I find most interesting.
CCL5, also known as RANTES, is one of the chemokines implicated in Ebola-associated inflammation, and it signals through CCR5 among other receptors. Leronlimab blocks CCR5.
That gives us a plausible hypothesis:
- Ebola infection stimulates the release of inflammatory chemokines.
- CCR5 signaling helps recruit certain immune cells into inflamed tissues.
- Blocking CCR5 might reduce some of the harmful recruitment and amplification of inflammation.
However, there is an important distinction: Leronlimab would not directly neutralize TNF-α, IL-6 or IL-1β, and blocking CCR5 would not eliminate all the pathways driving the cytokine storm. Some chemokines signal through other receptors, and some CCR5-dependent recruitment may be beneficial.
A further question is whether CCR5 blockade could interrupt a damaging feedback loop without impairing viral clearance. That is a testable hypothesis, not an established therapeutic effect.
### The experiment I would find most informative
I would want to know whether blocking CCR5 in an appropriate Ebola disease model reduces vascular leakage, coagulation abnormalities and organ injury, and whether that occurs without increasing viral load or delaying viral clearance. Survival would ultimately be a crucial outcome.
If the intervention improved those measures, it would provide a much stronger rationale for studying Leronlimab as an adjunct to antiviral treatment.
My conclusion: Your intuition is biologically sound. Ebola and severe COVID-19 share important features of immune dysregulation, and macrophages are central to Ebola pathogenesis.
CCR5 blockade is therefore a reasonable research hypothesis—but the critical question is whether CCR5-mediated inflammation is sufficiently important to alter the course of Ebola disease, rather than simply being one part of a much larger inflammatory network.
2
